Revealing the cost of Type II diabetes in Europe View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2002-07

AUTHORS

B. Jönsson

ABSTRACT

AIMS/HYPOTHESIS: 'The Cost of Diabetes in Europe-Type II study' is the first coordinated attempt to measure total healthcare costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries - Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. METHODS: A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population. RESULTS: The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type II diabetes. CONCLUSION/INTERPRETATION: Type II diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management. More... »

PAGES

s5-s12

Journal

TITLE

Diabetologia

ISSUE

Suppl 1

VOLUME

45

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-002-0858-x

DOI

http://dx.doi.org/10.1007/s00125-002-0858-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015709744

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27942782


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Stockholm School of Economics", 
          "id": "https://www.grid.ac/institutes/grid.419684.6", 
          "name": [
            "Centre for Health Economics, Stockholm School of Economics, Box 6501, 113 83, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "J\u00f6nsson", 
        "givenName": "B.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2796.1998.00388.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002416497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07019-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018881858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.0954-6820.1983.tb08543.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028294983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1096-9136(199712)14:5+3.0.co;2-r", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038156622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurpub/8.3.210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044003781"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.159.16.1873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045010653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.78.4.8157701", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064318628"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.21.2.296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.21.4.518", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.21.9.1414", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.22.5.773", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074551804", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075091451", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079565268", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081834605", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-07", 
    "datePublishedReg": "2002-07-01", 
    "description": "AIMS/HYPOTHESIS: 'The Cost of Diabetes in Europe-Type II study' is the first coordinated attempt to measure total healthcare costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries - Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom.\nMETHODS: A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population.\nRESULTS: The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type II diabetes.\nCONCLUSION/INTERPRETATION: Type II diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00125-002-0858-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "45"
      }
    ], 
    "name": "Revealing the cost of Type II diabetes in Europe", 
    "pagination": "s5-s12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4ad9da625557e1f2215205b0b033c3e6e8a154219b7cc4edb4de5025a49d0ea2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27942782"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-002-0858-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015709744"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-002-0858-x", 
      "https://app.dimensions.ai/details/publication/pub.1015709744"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89793_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00125-002-0858-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-002-0858-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-002-0858-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-002-0858-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-002-0858-x'


 

This table displays all metadata directly associated to this object as RDF triples.

109 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-002-0858-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nc01bf288aa18444885053b3ce4dc8eed
4 schema:citation https://app.dimensions.ai/details/publication/pub.1074551804
5 https://app.dimensions.ai/details/publication/pub.1075091451
6 https://app.dimensions.ai/details/publication/pub.1079565268
7 https://app.dimensions.ai/details/publication/pub.1081834605
8 https://doi.org/10.1001/archinte.159.16.1873
9 https://doi.org/10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r
10 https://doi.org/10.1016/s0140-6736(98)07019-6
11 https://doi.org/10.1093/eurpub/8.3.210
12 https://doi.org/10.1111/j.0954-6820.1983.tb08543.x
13 https://doi.org/10.1111/j.1365-2796.1998.00388.x
14 https://doi.org/10.1210/jcem.78.4.8157701
15 https://doi.org/10.2337/diacare.21.2.296
16 https://doi.org/10.2337/diacare.21.4.518
17 https://doi.org/10.2337/diacare.21.9.1414
18 https://doi.org/10.2337/diacare.22.5.773
19 schema:datePublished 2002-07
20 schema:datePublishedReg 2002-07-01
21 schema:description AIMS/HYPOTHESIS: 'The Cost of Diabetes in Europe-Type II study' is the first coordinated attempt to measure total healthcare costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries - Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. METHODS: A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population. RESULTS: The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type II diabetes. CONCLUSION/INTERPRETATION: Type II diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree true
25 schema:isPartOf N19a1ebf518aa45cb881d705bbd54963a
26 Nadc008cb5ef44e6f8e1ba819cd53e087
27 sg:journal.1001482
28 schema:name Revealing the cost of Type II diabetes in Europe
29 schema:pagination s5-s12
30 schema:productId N011fe26d32c642198da28adc379d3a87
31 N0dde2c2d9b114e44aad4500b77f1a027
32 N3ad0f4a223ba43cda46856a160ef74fe
33 N3facd515b02449f492693e236d1adc0c
34 Nb08aecd41d274a799c0fedc30e81f54d
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015709744
36 https://doi.org/10.1007/s00125-002-0858-x
37 schema:sdDatePublished 2019-04-11T09:53
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher N8b19e7cfa81a47d99e9f1a1da6ca9346
40 schema:url https://link.springer.com/10.1007%2Fs00125-002-0858-x
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N011fe26d32c642198da28adc379d3a87 schema:name nlm_unique_id
45 schema:value 0006777
46 rdf:type schema:PropertyValue
47 N0dde2c2d9b114e44aad4500b77f1a027 schema:name doi
48 schema:value 10.1007/s00125-002-0858-x
49 rdf:type schema:PropertyValue
50 N19a1ebf518aa45cb881d705bbd54963a schema:issueNumber Suppl 1
51 rdf:type schema:PublicationIssue
52 N3ad0f4a223ba43cda46856a160ef74fe schema:name readcube_id
53 schema:value 4ad9da625557e1f2215205b0b033c3e6e8a154219b7cc4edb4de5025a49d0ea2
54 rdf:type schema:PropertyValue
55 N3facd515b02449f492693e236d1adc0c schema:name dimensions_id
56 schema:value pub.1015709744
57 rdf:type schema:PropertyValue
58 N8b19e7cfa81a47d99e9f1a1da6ca9346 schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 Nadc008cb5ef44e6f8e1ba819cd53e087 schema:volumeNumber 45
61 rdf:type schema:PublicationVolume
62 Nb08aecd41d274a799c0fedc30e81f54d schema:name pubmed_id
63 schema:value 27942782
64 rdf:type schema:PropertyValue
65 Nc01bf288aa18444885053b3ce4dc8eed rdf:first Nce941dcf8f1d4aa892785d4b26a230f0
66 rdf:rest rdf:nil
67 Nce941dcf8f1d4aa892785d4b26a230f0 schema:affiliation https://www.grid.ac/institutes/grid.419684.6
68 schema:familyName Jönsson
69 schema:givenName B.
70 rdf:type schema:Person
71 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
72 schema:name Medical and Health Sciences
73 rdf:type schema:DefinedTerm
74 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
75 schema:name Clinical Sciences
76 rdf:type schema:DefinedTerm
77 sg:journal.1001482 schema:issn 0012-186X
78 1432-0428
79 schema:name Diabetologia
80 rdf:type schema:Periodical
81 https://app.dimensions.ai/details/publication/pub.1074551804 schema:CreativeWork
82 https://app.dimensions.ai/details/publication/pub.1075091451 schema:CreativeWork
83 https://app.dimensions.ai/details/publication/pub.1079565268 schema:CreativeWork
84 https://app.dimensions.ai/details/publication/pub.1081834605 schema:CreativeWork
85 https://doi.org/10.1001/archinte.159.16.1873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045010653
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r schema:sameAs https://app.dimensions.ai/details/publication/pub.1038156622
88 rdf:type schema:CreativeWork
89 https://doi.org/10.1016/s0140-6736(98)07019-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018881858
90 rdf:type schema:CreativeWork
91 https://doi.org/10.1093/eurpub/8.3.210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044003781
92 rdf:type schema:CreativeWork
93 https://doi.org/10.1111/j.0954-6820.1983.tb08543.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028294983
94 rdf:type schema:CreativeWork
95 https://doi.org/10.1111/j.1365-2796.1998.00388.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002416497
96 rdf:type schema:CreativeWork
97 https://doi.org/10.1210/jcem.78.4.8157701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064318628
98 rdf:type schema:CreativeWork
99 https://doi.org/10.2337/diacare.21.2.296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748112
100 rdf:type schema:CreativeWork
101 https://doi.org/10.2337/diacare.21.4.518 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748197
102 rdf:type schema:CreativeWork
103 https://doi.org/10.2337/diacare.21.9.1414 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748416
104 rdf:type schema:CreativeWork
105 https://doi.org/10.2337/diacare.22.5.773 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748748
106 rdf:type schema:CreativeWork
107 https://www.grid.ac/institutes/grid.419684.6 schema:alternateName Stockholm School of Economics
108 schema:name Centre for Health Economics, Stockholm School of Economics, Box 6501, 113 83, Stockholm, Sweden
109 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...